ATE398124T1 - Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron - Google Patents

Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron

Info

Publication number: ATE398124T1
Authority: AT; Austria
Prior art keywords: compounds; formula; aldosterone; imidazoä1; methods
Prior art date: 2002-11-18

Application number

AT03767563T

Other languages

English (en)

Inventor

Fariborz Firooznia

Original Assignee

Novartis Pharma Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-11-18

Filing date

2003-11-17

Publication date

2008-07-15

2003-11-17 Application filed by Novartis Pharma Gmbh filed Critical Novartis Pharma Gmbh

2008-07-15 Application granted granted Critical

2008-07-15 Publication of ATE398124T1 publication Critical patent/ATE398124T1/de

Links

JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical class C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 title 1
201000010099 disease Diseases 0.000 title 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 abstract 3
108010009911 Cytochrome P-450 CYP11B2 Proteins 0.000 abstract 2
108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 abstract 2
102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 abstract 2
102100024329 Cytochrome P450 11B2, mitochondrial Human genes 0.000 abstract 2
206010020772 Hypertension Diseases 0.000 abstract 2
PQSUYGKTWSAVDQ-ZVIOFETBSA-N Aldosterone Chemical compound C([C@@]1([C@@H](C(=O)CO)CC[C@H]1[C@@H]1CC2)C=O)[C@H](O)[C@@H]1[C@]1(C)C2=CC(=O)CC1 PQSUYGKTWSAVDQ-ZVIOFETBSA-N 0.000 abstract 1
PQSUYGKTWSAVDQ-UHFFFAOYSA-N Aldosterone Natural products C1CC2C3CCC(C(=O)CO)C3(C=O)CC(O)C2C2(C)C1=CC(=O)CC2 PQSUYGKTWSAVDQ-UHFFFAOYSA-N 0.000 abstract 1
201000001320 Atherosclerosis Diseases 0.000 abstract 1
206010007559 Cardiac failure congestive Diseases 0.000 abstract 1
102000008186 Collagen Human genes 0.000 abstract 1
108010035532 Collagen Proteins 0.000 abstract 1
206010048554 Endothelial dysfunction Diseases 0.000 abstract 1
206010016654 Fibrosis Diseases 0.000 abstract 1
206010019280 Heart failures Diseases 0.000 abstract 1
208000019025 Hypokalemia Diseases 0.000 abstract 1
208000008589 Obesity Diseases 0.000 abstract 1
208000001647 Renal Insufficiency Diseases 0.000 abstract 1
229940124639 Selective inhibitor Drugs 0.000 abstract 1
229960002478 aldosterone Drugs 0.000 abstract 1
230000015572 biosynthetic process Effects 0.000 abstract 1
208000020832 chronic kidney disease Diseases 0.000 abstract 1
208000022831 chronic renal failure syndrome Diseases 0.000 abstract 1
229920001436 collagen Polymers 0.000 abstract 1
208000029078 coronary artery disease Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
230000008694 endothelial dysfunction Effects 0.000 abstract 1
230000004761 fibrosis Effects 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
208000017169 kidney disease Diseases 0.000 abstract 1
201000006370 kidney failure Diseases 0.000 abstract 1
230000001404 mediated effect Effects 0.000 abstract 1
208000010125 myocardial infarction Diseases 0.000 abstract 1
235000020824 obesity Nutrition 0.000 abstract 1
239000002831 pharmacologic agent Substances 0.000 abstract 1
208000024896 potassium deficiency disease Diseases 0.000 abstract 1
230000002265 prevention Effects 0.000 abstract 1
238000007634 remodeling Methods 0.000 abstract 1
208000037803 restenosis Diseases 0.000 abstract 1
208000011580 syndromic disease Diseases 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Diabetes (AREA)
Hematology (AREA)
Obesity (AREA)
Vascular Medicine (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT03767563T 2002-11-18 2003-11-17 Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron ATE398124T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US42732502P	2002-11-18	2002-11-18

Publications (1)

Publication Number	Publication Date
ATE398124T1 true ATE398124T1 (de)	2008-07-15

Family

ID=32326521

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03767563T ATE398124T1 (de)	2002-11-18	2003-11-17	Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron

Country Status (13)

Country	Link
US (2)	US7223866B2 (de)
EP (1)	EP1565463B1 (de)
JP (1)	JP2006508970A (de)
CN (1)	CN100447142C (de)
AT (1)	ATE398124T1 (de)
AU (1)	AU2003292039A1 (de)
BR (1)	BR0316306A (de)
CA (1)	CA2505752A1 (de)
DE (1)	DE60321593D1 (de)
ES (1)	ES2305520T3 (de)
HK (1)	HK1081540A1 (de)
PT (1)	PT1565463E (de)
WO (1)	WO2004046145A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1569896B1 (de) *	2002-12-06	2007-08-15	Bayer HealthCare AG	Tetrahydronaphtalen-derivate
JP4440113B2 (ja) *	2002-12-09	2010-03-24	バイエル・ヘルスケア・アクチェンゲゼルシャフト	バニロイド受容体アンタゴニストとしてのテトラヒドロ−ナフタレン誘導体
EP1853261B1 (de) *	2005-03-03	2017-01-11	Universität des Saarlandes	Selektive hemmstoffe humaner corticoidsynthasen
TW200716636A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
TW200716105A (en) *	2005-05-31	2007-05-01	Speedel Experimenta Ag	Imidazole compounds
TW200716634A (en)	2005-05-31	2007-05-01	Speedel Experimenta Ag	Heterocyclic spiro-compounds
GT200600381A (es)	2005-08-25	2007-03-28		Compuestos organicos
EP1842543A1 (de)	2006-04-05	2007-10-10	Speedel Pharma AG	Pharmazeutishe Zusammensetzung enthaltend einen Aldosteron-Synthase-Inhibitor und einen Mineralkorticoidrezeptor-Antagonist
EP2118101B1 (de) *	2007-03-09	2012-09-26	Probiodrug AG	Imidazo[1,5-a]pyridinderivate als inhibitoren von glutaminylcyclase
ES2448839T3 (es)	2007-11-01	2014-03-17	Bristol-Myers Squibb Company	Compuestos no esteroideos útiles como moderadores de la actividad del receptor de glucocorticoides AP-1 y/o NF-kappa b y uso de los mismos
EP2095819A1 (de) *	2008-02-28	2009-09-02	Maastricht University	N-Benzyl-Imidazolderivate und deren Verwendung als Aldosteronsynthaseinhibitoren
ME01923B (me)	2009-05-28	2015-05-20	Novartis Ag	Supstituisani derivati aminopropionske kiseline kao inhibitori neprilizina
SG176010A1 (en)	2009-05-28	2011-12-29	Novartis Ag	Substituted aminobutyric derivatives as neprilysin inhibitors
JO2967B1 (en)	2009-11-20	2016-03-15	نوفارتس ايه جي	Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors
JP5575913B2 (ja)	2009-11-30	2014-08-20	ノバルティスアーゲー	アルドステロン合成酵素阻害剤としてのイミダゾール誘導体
US8673974B2 (en)	2010-11-16	2014-03-18	Novartis Ag	Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors
ES2683350T3 (es)	2011-07-08	2018-09-26	Novartis Ag	Método para tratar la aterosclerosis en sujetos con alto nivel de triglicéridos
US20140235667A1 (en) *	2011-09-22	2014-08-21	Merck Sharp & Dohme Corp.	Imidazopyridyl compounds as aldosterone synthase inhibitors
EP2757884B1 (de)	2011-09-22	2022-07-27	Merck Sharp & Dohme LLC	Pyrazolopyridylverbindungen als aldosteronsynthasehemmer
US9193724B2 (en)	2011-09-22	2015-11-24	Merck Sharp & Dohme Corp.	Triazolopyridyl compounds as aldosterone synthase inhibitors
IN2014DN06781A (de)	2012-01-17	2015-05-22	Novartis Ag
UY35144A (es)	2012-11-20	2014-06-30	Novartis Ag	Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
MA38330B1 (fr)	2013-02-14	2016-09-30	Novartis Ag	Dérivés d'acide phosphonique butanoïque de bisphénol substitués en qualité d'inhibiteurs de nep (endopeptidase neutre)
CN105705167A (zh)	2013-07-25	2016-06-22	诺华股份有限公司	合成的apelin多肽的生物缀合物
EP3024845A1 (de)	2013-07-25	2016-06-01	Novartis AG	Cyclische polypeptide zur behandlung von herzinsuffizienz
JP2018507187A (ja)	2015-01-23	2018-03-15	ノバルティスアーゲー	改善された半減期を有する合成アペリン脂肪酸コンジュゲート
GB201511790D0 (en) *	2015-07-06	2015-08-19	Iomet Pharma Ltd	Pharmaceutical compound
JOP20190086A1 (ar)	2016-10-21	2019-04-18	Novartis Ag	مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
UY38072A (es)	2018-02-07	2019-10-01	Novartis Ag	Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos
CN113166101A (zh)	2018-11-27	2021-07-23	诺华股份有限公司	作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状五聚体化合物
UY38485A (es)	2018-11-27	2020-06-30	Novartis Ag	Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación
EP3887388A1 (de)	2018-11-27	2021-10-06	Novartis AG	Zyklische peptide als proprotein-konvertase-subtilisin-/kexin typ 9 (pcsk9) zur behandlung von stoffwechselstörungen
TW202333563A (zh)	2021-11-12	2023-09-01	瑞士商諾華公司	用於治療疾病或障礙之二胺基環戊基吡啶衍生物
AR127698A1 (es)	2021-11-23	2024-02-21	Novartis Ag	Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB2101595B (en) *	1981-06-22	1985-05-30	Ciba Geigy Ag	Substituted imidazo(1,5-a)pyridines, process for their manufacture, pharmaceutical preparations containing these compounds and their therapeutic application
US4588732A (en) *	1982-12-21	1986-05-13	Ciba-Geigy Corporation	Certain imidazo(1,5-a)pyridine derivatives and their use as thromboxane synthetase inhibitors
US4617307A (en) *	1984-06-20	1986-10-14	Ciba-Geigy Corporation	Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors
US4470986A (en) *	1982-12-21	1984-09-11	Ciba-Geigy Corporation	Certain imidazo (1,5-A) pyridine aliphatic carboxylic acid derivatives and their use as selective thromboxane inhibitors
US5428160A (en) *	1982-12-21	1995-06-27	Ciba-Geigy Corporation	Substituted imidazo[5-a]pyridine derviatives and other substituted bicyclic derivatives
US4889861A (en)	1982-12-21	1989-12-26	Ciba-Geigy Corp.	Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors
JPS615076A (ja) *	1984-06-19	1986-01-10	Toyama Chem Co Ltd	新規な１，４−ジヒドロピリジン誘導体およびその塩
GB8510541D0 (en) *	1985-04-25	1985-05-30	Wyeth John & Brother Ltd	Heterocyclic compounds
US5798364A (en)	1992-03-26	1998-08-25	Merck Patent Gesellschaft Mit Beschrankter Haftung	Imidazopyridines
US6150347A (en)	1992-04-21	2000-11-21	The Curators Of The University Of Missouri	Use of aldosterone antagonists to inhibit myocardial fibrosis
US5529992A (en)	1992-04-21	1996-06-25	Curators Of The University Of Missouri	Method for inhibiting myocardial fibrosis by administering an aldosterone antagonist which suppresses aldoster one receptors
JPH0971586A (ja) *	1995-09-07	1997-03-18	Yamanouchi Pharmaceut Co Ltd	新規な二環性縮合イミダゾール誘導体
DE19701257A1 (de) *	1997-01-17	1998-07-23	Hannecke Wolf D Kunststoff	Säulenpräsentationssystem in Modulbauweise zur Schaustellung von Waren oder Prospektmaterial und insbesondere von dünnen Gegenständen
US6887870B1 (en)	1999-10-12	2005-05-03	Bristol-Myers Squibb Company	Heterocyclic sodium/proton exchange inhibitors and method

2003
- 2003-11-17 JP JP2004552632A patent/JP2006508970A/ja active Pending
- 2003-11-17 ES ES03767563T patent/ES2305520T3/es not_active Expired - Lifetime
- 2003-11-17 CA CA002505752A patent/CA2505752A1/en not_active Abandoned
- 2003-11-17 WO PCT/EP2003/012851 patent/WO2004046145A1/en active IP Right Grant
- 2003-11-17 PT PT03767563T patent/PT1565463E/pt unknown
- 2003-11-17 EP EP03767563A patent/EP1565463B1/de not_active Expired - Lifetime
- 2003-11-17 AT AT03767563T patent/ATE398124T1/de not_active IP Right Cessation
- 2003-11-17 DE DE60321593T patent/DE60321593D1/de not_active Expired - Lifetime
- 2003-11-17 AU AU2003292039A patent/AU2003292039A1/en not_active Abandoned
- 2003-11-17 US US10/534,631 patent/US7223866B2/en not_active Expired - Fee Related
- 2003-11-17 BR BR0316306-7A patent/BR0316306A/pt not_active IP Right Cessation
- 2003-11-17 CN CNB2003801035050A patent/CN100447142C/zh not_active Expired - Fee Related
2006
- 2006-02-06 HK HK06101571.9A patent/HK1081540A1/xx not_active IP Right Cessation
2007
- 2007-04-24 US US11/739,290 patent/US7713991B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
ES2305520T3 (es)	2008-11-01
US20070197582A1 (en)	2007-08-23
EP1565463A1 (de)	2005-08-24
US20060058342A1 (en)	2006-03-16
EP1565463B1 (de)	2008-06-11
US7223866B2 (en)	2007-05-29
PT1565463E (pt)	2008-09-10
DE60321593D1 (de)	2008-07-24
BR0316306A (pt)	2005-09-27
AU2003292039A1 (en)	2004-06-15
HK1081540A1 (en)	2006-05-19
CN1711262A (zh)	2005-12-21
CN100447142C (zh)	2008-12-31
JP2006508970A (ja)	2006-03-16
CA2505752A1 (en)	2004-06-03
US7713991B2 (en)	2010-05-11
WO2004046145A1 (en)	2004-06-03

Legal Events

Date

Code

Title

Description

2008-12-15

UEP

Publication of translation of european patent specification

Ref document number: 1565463

Country of ref document: EP

2011-08-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE398124T1 (de)	2008-07-15	Imidazoä1,5üa pyridin-derivate und methoden zur behandlung von krankheiten in verbindung mit aldosteron
ATE335744T1 (de)	2006-09-15	Organische verbindungen als mittel zur behandlung von aldosteronbedingten zuständen
WO2008076336A3 (en)	2008-12-04	Imidazoles as aldosterone synthase inhibitors
WO2007117982A3 (en)	2007-12-13	Organic compounds
AU2003290335A1 (en)	2004-07-22	Piperidinyl-thiazole carboxamide derivatives for altering vascular tone
EA201070339A1 (ru)	2010-10-29	Активаторы растворимой гуанилатциклазы
UA84453C2 (ru)	2008-10-27	Применение производных метиленамида для лечения сердечно-сосудистых заболеваний
ME01530B (me)	2011-10-10	Polimorfni oblici 3- (4-amino-1- okso-1, 3-dihidro- izoindol -2-il)-piperidin-2,6- diona
NO20082834L (no)	2008-08-21	2-(fenyl eller heterosyklisk)-1H-fenantro[9,10-D]imidazoler som MPGES-1-inhibitorer
WO2006086544A3 (en)	2006-12-21	Therapeutic combination of a vegf antagonist (vegf trap) and an anti-hypertensive agent
MY149861A (en)	2013-10-31	Prolyl hydroxylase inhibitors
EA201000915A1 (ru)	2011-02-28	Ингибиторы пролилгидроксилазы
WO2009079412A3 (en)	2009-08-20	Reverse transcriptase inhibitors
BR0316585A (pt)	2005-10-04	Derivados de ácido glioxìlico aril, ariloxi e alquiloxi 1h-indol-3-il substituìdos como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
MA28170A1 (fr)	2006-09-01	Nouveaux derives de ceto-oxadiazole comme inhibiteurs de la cathepsine
ATE520690T1 (de)	2011-09-15	Piperidinderivate als renin-inhibitoren
BR0316574A (pt)	2005-10-04	Derivados de ácido acético 3-carbonil-1h-indol-1-il substituìdo como inibidores do inibidor-1 do ativador do plasminogênio (pai-1)
NO20060247L (no)	2006-03-13	Substituerte spirobenzazepiner
NO20092246L (no)	2009-07-01	Urea og sulfamidderivater som tafiainhibitorer
NO20004502L (no)	2000-11-07	Nye sammensetninger av eprosartan
ATE410235T1 (de)	2008-10-15	Behandlung von ballastwasser
ATE310005T1 (de)	2005-12-15	1- oder 3-thia-benzonaphthoazulene als inhibitoren der produktion von tumornekrosefaktor und zwischenprodukte für deren herstellung
IL164397A0 (en)	2005-12-18	1-Oxa-3-aza-dibenzoazulenes as inhibitors of tumour necrosis factor production and intermediates forthe production thereof
DE602004021145D1 (de)	2009-06-25	NEUE SUBSTITUIERTE THIOPHENPYRIMIDINONDERIVATE ALS INHIBITOREN VON 17ß-HYDROXYSTEROIDDEHYDROGENASE
AU2002302472A1 (en)	2002-10-08	Use of ikk-beta inhibitors and method for discovery of said inhibitors